Clinical Trial Update: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

This is an early-phase (Phase 1) clinical trial update for Iomab-ACT, which combines 131-I-labeled apamistamab with CD19-targeted CAR T-cell therapy for relapse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CD19-targeted CAR-T cell therapy
• Iomab-ACT (131-I apamistamab) (131I-apamistamab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: B-ALL, DLBCL | EARLY_Phase 1 | Status: RECRUITING